CLDX
Price
$23.78
Change
+$1.02 (+4.48%)
Updated
Jan 17 closing price
Capitalization
1.58B
43 days until earnings call
VRNA
Price
$51.89
Change
-$1.75 (-3.26%)
Updated
Jan 17 closing price
Capitalization
4.25B
39 days until earnings call
Ad is loading...

CLDX vs VRNA

Header iconCLDX vs VRNA Comparison
Open Charts CLDX vs VRNABanner chart's image
Celldex Therapeutics
Price$23.78
Change+$1.02 (+4.48%)
Volume$854.67K
Capitalization1.58B
Verona Pharma
Price$51.89
Change-$1.75 (-3.26%)
Volume$2.02M
Capitalization4.25B
CLDX vs VRNA Comparison Chart
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. VRNA commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and VRNA is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CLDX: $23.78 vs. VRNA: $51.89)
Brand notoriety: CLDX and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 81% vs. VRNA: 172%
Market capitalization -- CLDX: $1.58B vs. VRNA: $4.25B
CLDX [@Biotechnology] is valued at $1.58B. VRNA’s [@Biotechnology] market capitalization is $4.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, VRNA is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 4 TA indicator(s) are bullish while VRNA’s TA Score has 3 bullish TA indicator(s).

  • CLDX’s TA Score: 4 bullish, 3 bearish.
  • VRNA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than VRNA.

Price Growth

CLDX (@Biotechnology) experienced а -2.34% price change this week, while VRNA (@Biotechnology) price change was +14.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CLDX is expected to report earnings on May 13, 2025.

VRNA is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRNA($4.25B) has a higher market cap than CLDX($1.58B). VRNA YTD gains are higher at: 11.736 vs. CLDX (-5.896). VRNA has higher annual earnings (EBITDA): -136.9M vs. CLDX (-171.06M). CLDX has more cash in the bank: 756M vs. VRNA (336M). CLDX has less debt than VRNA: CLDX (3.09M) vs VRNA (122M). CLDX has higher revenues than VRNA: CLDX (9.98M) vs VRNA (5.62M).
CLDXVRNACLDX / VRNA
Capitalization1.58B4.25B37%
EBITDA-171.06M-136.9M125%
Gain YTD-5.89611.736-50%
P/E RatioN/AN/A-
Revenue9.98M5.62M177%
Total Cash756M336M225%
Total Debt3.09M122M3%
FUNDAMENTALS RATINGS
CLDX vs VRNA: Fundamental Ratings
CLDX
VRNA
OUTLOOK RATING
1..100
5592
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
88
Overvalued
PROFIT vs RISK RATING
1..100
485
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
8535
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (57) in the Biotechnology industry is in the same range as VRNA (88) in the Pharmaceuticals Other industry. This means that CLDX’s stock grew similarly to VRNA’s over the last 12 months.

VRNA's Profit vs Risk Rating (5) in the Pharmaceuticals Other industry is somewhat better than the same rating for CLDX (48) in the Biotechnology industry. This means that VRNA’s stock grew somewhat faster than CLDX’s over the last 12 months.

CLDX's SMR Rating (96) in the Biotechnology industry is in the same range as VRNA (98) in the Pharmaceuticals Other industry. This means that CLDX’s stock grew similarly to VRNA’s over the last 12 months.

VRNA's Price Growth Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for CLDX (85) in the Biotechnology industry. This means that VRNA’s stock grew somewhat faster than CLDX’s over the last 12 months.

VRNA's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as CLDX (100) in the Biotechnology industry. This means that VRNA’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXVRNA
RSI
ODDS (%)
N/A
Bearish Trend 11 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
75%
Bearish Trend 11 days ago
79%
Momentum
ODDS (%)
Bullish Trend 11 days ago
83%
N/A
MACD
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 11 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
83%
Bearish Trend 11 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 11 days ago
82%
Advances
ODDS (%)
Bullish Trend 16 days ago
83%
Bullish Trend 27 days ago
78%
Declines
ODDS (%)
Bearish Trend 20 days ago
79%
Bearish Trend 13 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
80%
Aroon
ODDS (%)
N/A
Bullish Trend 11 days ago
82%
View a ticker or compare two or three
Ad is loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PALC50.220.53
+1.07%
Pacer Lunt Large Cap Mlt Ftr Alt ETF
IEV53.530.29
+0.54%
iShares Europe ETF
GBPUSD1.22N/A
N/A
United Kingdom Pound - United States Dollar
CNYNZD0.24N/A
N/A
China Yuan - New Zealand Dollar
CADEUR0.67N/A
N/A
Canadian Dollar - Euro

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with KRYS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+4.48%
KRYS - CLDX
56%
Loosely correlated
+2.47%
ALT - CLDX
46%
Loosely correlated
+2.24%
AXON - CLDX
43%
Loosely correlated
+1.37%
NTLA - CLDX
42%
Loosely correlated
+0.85%
BEAM - CLDX
42%
Loosely correlated
+0.17%
More

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with VCYT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
-3.26%
VCYT - VRNA
38%
Loosely correlated
-1.27%
AKBA - VRNA
35%
Loosely correlated
+7.25%
TRDA - VRNA
33%
Loosely correlated
+1.20%
CLDX - VRNA
32%
Poorly correlated
+4.48%
AVXL - VRNA
32%
Poorly correlated
-9.26%
More